TSHR and hyperthyroidism: Such small-molecule antagonists of TSHR attract much attention from scientists who are dedicated to developing new treatments for Graves’ disease, a pathological condition caused by binding of stimulatory autoantibodies to TSHR to induce hyperthyroidism.